Intellia Therapeutics, Inc. (NTLA) Expected to Post FY2017 Earnings of ($1.74) Per Share
Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Jefferies Group raised their FY2017 EPS estimates for shares of Intellia Therapeutics in a research note issued to investors on Tuesday. Jefferies Group analyst M. Raycroft now forecasts that the company will earn ($1.74) per share for the year, up from their prior forecast of ($1.99). Jefferies Group currently has a “Buy” rating and a $42.00 price target on the stock. Jefferies Group also issued estimates for Intellia Therapeutics’ Q4 2017 earnings at ($0.49) EPS, FY2018 earnings at ($2.34) EPS, FY2019 earnings at ($2.78) EPS, FY2020 earnings at ($2.44) EPS and FY2021 earnings at ($2.31) EPS.
Other analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Cann restated a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Chardan Capital reiterated a “buy” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Intellia Therapeutics in a report on Wednesday, August 2nd. Leerink Swann boosted their price objective on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday. They noted that the move was a valuation call. Finally, TheStreet upgraded shares of Intellia Therapeutics from a “d+” rating to a “c-” rating in a report on Thursday, July 6th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $29.50.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 27.19% and a negative net margin of 215.92%. The firm had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $5.83 million. During the same period in the prior year, the firm posted ($0.22) earnings per share. The firm’s quarterly revenue was up 49.0% on a year-over-year basis.
Several large investors have recently made changes to their positions in NTLA. ARK Investment Management LLC grew its position in Intellia Therapeutics by 118.9% in the 2nd quarter. ARK Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after purchasing an additional 94,960 shares during the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 10.2% in the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after purchasing an additional 92,580 shares during the last quarter. OxFORD Asset Management LLP bought a new position in Intellia Therapeutics in the 2nd quarter worth about $1,132,000. GSA Capital Partners LLP bought a new position in Intellia Therapeutics in the 2nd quarter worth about $907,000. Finally, State Street Corp grew its position in Intellia Therapeutics by 52.0% in the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after purchasing an additional 56,363 shares during the last quarter. 47.77% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.